Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Swiss Exchange  >  Basilea Pharmaceutica AG    BSLN   CH0011432447


SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Basilea Pharmaceutica : reports acceptance for regulatory review of Pfizer's marketing authorization application for antifungal isavuconazole (Cresemba®) in invasive aspergillosis in China

11/25/2020 | 01:15am EST
  • Second indication under review following mucormycosis

Basel, Switzerland, November 25, 2020

Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that the marketing authorization application (MAA) for the antifungal isavuconazole (Cresemba®) for the treatment of adult patients with invasive aspergillosis, which was submitted by Basilea’s license partner Pfizer Inc. (NYSE: PFE, “Pfizer”), has been accepted for regulatory review by the Center for Drug Evaluation at the National Medical Products Administration (NMPA) of China. In August 2020, Basilea had announced that an MAA for Cresemba for the treatment of mucormycosis was accepted for review by the NMPA.

David Veitch, Chief Executive Officer, said: “Invasive aspergillosis and mucormycosis are the two most frequent forms of invasive mold infections and important causes of morbidity and mortality in patients with hematologic malignancies undergoing intensive chemotherapy regimens. China is commercially a very important market for Cresemba, accounting for more than 15 percent of the global market for newer antifungals. We are therefore very pleased with the progress Pfizer is making in China. The acceptance of the isavuconazole marketing authorization applications for regulatory review is an important milestone in bringing Cresemba to the Chinese market and addressing the unmet medical needs of patients suffering from invasive mold infections.”

In November 2017, Basilea and Pfizer extended their existing license agreement for Europe (excluding the Nordics), Russia, Turkey and Israel, to include China, including Hong Kong and Macao, and sixteen countries in the Asia Pacific region. Under the agreement with Pfizer, Basilea is still eligible for regulatory and sales milestone payments of up to approximately USD 630 million, in addition to receiving mid-teen royalties on sales.

Cresemba has been approved in more than 50 countries to date and is currently marketed in 48 countries, including the United States, most EU member states and several additional countries inside and outside of Europe. For the twelve-month period to the end of June 2020, total "in-market" sales of Cresemba amounted to USD 230 million, a 30 percent growth year-on-year.1

About Cresemba (isavuconazole)

Isavuconazole is an intravenous (i.v.) and oral azole antifungal, commercialized under the trade name Cresemba. In the 27 European Union member states, as well as in Iceland, Liechtenstein, Norway and the U.K., isavuconazole is approved for the treatment of adult patients with invasive aspergillosis and for the treatment of adult patients with mucormycosis for whom amphotericin B is inappropriate.2 Cresemba is also approved in the United States and several additional countries in Europe and beyond.3 It has orphan drug designation in the U.S., Europe and Australia for its approved indications. Basilea has entered into several license and distribution agreements for isavuconazole covering the United States, Europe, China, Japan, Latin America, Asia-Pacific, the Middle East and North Africa region, Canada, Russia, Turkey and Israel.

About Basilea

Basilea Pharmaceutica Ltd. is a commercial-stage biopharmaceutical company, focused on the development of products that address the medical challenges in the therapeutic areas of oncology and infectious diseases. With two commercialized drugs, the company is committed to discovering, developing and commercializing innovative pharmaceutical products to meet the medical needs of patients with serious and life-threatening conditions. Basilea Pharmaceutica Ltd. is headquartered in Basel, Switzerland and listed on the SIX Swiss Exchange (SIX: BSLN). Additional information can be found at Basilea's website www.basilea.com.


This communication expressly or implicitly contains certain forward-looking statements, such as "believe", "assume", "expect", "forecast", "project", "may", "could", "might", "will" or similar expressions concerning Basilea Pharmaceutica Ltd. and its business, including with respect to the progress, timing and completion of research, development and clinical studies for product candidates. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Basilea Pharmaceutica Ltd. to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Basilea Pharmaceutica Ltd. is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

For further information, please contact:

Peer Nils Schröder, PhD

Head of Corporate Communications & Investor Relations
Phone+41 61 606 1102

 This press release can be downloaded from www.basilea.com.


  1. IQVIA, June 2020. In-market sales reported as moving annual total (MAT) in U.S. Dollar corrected for currency fluctuations.
  2. European Public Assessment Report (EPAR) Cresemba: http://www.ema.europa.eu [Accessed: November 24, 2020]
  3. The registration status and approved indications may vary from country to country.


  • Press release (PDF)

© OMX, source OMX

01/11BASILEA PHARMACEUTICA : 2020 Revenue Projected to Decline to $144 Million
01/11PRESS RELEASE : Basilea reports preliminary 2020 -2-
01/11PRESS RELEASE : Basilea reports preliminary 2020 revenue and portfolio progress
01/07Basilea's Japanese Partner Enrolls Patients for Phase 3 Study of Invasive Asp..
01/07PRESS RELEASE : Basilea's partner Asahi Kasei Pharma completes patient enrolment..
01/07Basilea's partner Asahi Kasei Pharma completes patient enrolment in phase 3 s..
2020Basilea's Invasive Aspergillosis Drug Isavuconazole Accepted For Regulatory R..
2020PRESS RELEASE : Basilea reports acceptance for regulatory review of Pfizer's mar..
2020BASILEA PHARMACEUTICA : reports acceptance for regulatory review of Pfizer's mar..
2020BASILEA PHARMACEUTICA : reports acceptance for regulatory review of Pfizer's mar..
More news
Sales 2020 134 M 151 M 151 M
Net income 2020 -19,3 M -21,8 M -21,8 M
Net Debt 2020 154 M 174 M 174 M
P/E ratio 2020 -24,9x
Yield 2020 -
Capitalization 578 M 653 M 652 M
EV / Sales 2020 5,47x
EV / Sales 2021 5,00x
Nbr of Employees 225
Free-Float 88,3%
Duration : Period :
Basilea Pharmaceutica AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BASILEA PHARMACEUTICA AG
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus HOLD
Number of Analysts 9
Average target price 84,43 CHF
Last Close Price 53,50 CHF
Spread / Highest target 134%
Spread / Average Target 57,8%
Spread / Lowest Target -2,80%
EPS Revisions
Managers and Directors
David Veitch Chief Executive Officer
Domenico Scala Chairman
Adesh Kaul Chief Financial Officer
Laurenz Kellenberger Chief Scientific Officer
Marc Engelhardt Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
MODERNA, INC.25.41%51 846
LONZA GROUP AG5.34%50 271
CELLTRION, INC.-13.65%38 245
SEAGEN INC.4.35%33 059